The Place of protease inhibitors in antiretroviral treatment
With the introduction of highly active antiretroviral therapy, a number of drugs have been developed. The best choice concerning which antiretroviral analogs to start is always under discussion, especially in the choice between non-nucleoside reverse transcriptase inhibitors-based therapies and rito...
Main Authors: | S.B. Tenore, P.R.A. Ferreira |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500012&lng=en&tlng=en |
Similar Items
-
Antiretroviral Theraphy: towards 2000
by: Semra ÇALANGU
Published: (1996-09-01) -
Outcomes and characteristics of patients on protease inhibitors at a tertiary level antiretroviral clinic
by: Michele Perks, et al.
Published: (2023-12-01) -
HIV Protease: Historical Perspective and Current Research
by: Irene T. Weber, et al.
Published: (2021-05-01) -
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
by: Ruxandra-Cristina Marin, et al.
Published: (2021-03-01) -
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
by: Tony Antoniou, et al.
Published: (2017-04-01)